PMS Health Center

Citations

1. Katz VL, et al. (2007). Primary and secondary dysmenorrhea, premenstrual syndrome, and premenstrual dysphoric disorder. In LO Eckert, GM Lentz, eds., Comprehensive Gynecology, 5th ed., pp. 901-913. Philadelphia: Mosby Elsevier.

Other Works Consulted

• Abajo FJ, Garcia-Rodriguez LA (2008). Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy. Archives of General Psychiatry, 65(7): 795-803.

• Berga SL, Spencer JB (2009). Premenstrual syndrome. In EG Nabel, ed., ACP Medicine, section 16, chap. 3. New York: WebMD.

• Davis AJ, Johnson SR (2000, reaffirmed 2008). Premenstrual syndrome. ACOG Practice Bulletin No. 15, pp. 1-9. Washington, DC: American College of Obstetricians and Gynecologists.

• Kwan I, Onwude JL (2009). Premenstrual syndrome, search date July 2009. Online version of BMJ Clinical Evidence: http://www.clinicalevidence.com.

• Reid RL (2008). Premenstrual syndrome. In RS Gibbs et al., eds., Danforth's Obstetrics and Gynecology, 10th ed., pp. 672-681. Philadelphia: Lippincott Williams and Wilkins.

• U.S. Food and Drug Administration (2005). FDA Public Health Advisory: Paroxetine. Available online: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051731.htm.

• Yonkers KA, et al. (2005). Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstetrics and Gynecology, 106(3): 492-501.